RESEARCH PROJECT COOPERATIVE AGREEMENT **Issue Date:** 09/04/2014
Department of Health and Human Services
National Institutes of Health
NATIONAL CANCER INSTITUTE

Grant Number: 5U01CA033193-33
FAIN: U01CA033193

Principal Investigator(s):
Kurt Straif

Project Title: Evaluation of Carcinogenic Risks to Humans

INTERNATIONAL AGENCY-RES CANCER
150 COURS ALBERT THOMAS
F-69372 LYON CEDEX 08, FRANCE,
FRANCE

Award e-mailed to: igo@iarc.fr

Budget Period: 09/01/2014 – 08/31/2015
Project Period: 09/01/1985 – 08/31/2015

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of $808,594 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to INTERNATIONAL AGENCY FOR RES ON CANCER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number U01CA033193. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Joy Kearse

Grants Management Officer
NATIONAL CANCER INSTITUTE

Additional information follows

SECTION I – AWARD DATA – 5U01CA033193-33

Award Calculation (U.S. Dollars)

Salaries and Wages	$381,055
Fringe Benefits	$127,020
Consultant Services	$40,829
Travel Costs	$2,203
Other Costs	$145,356
Federal Direct Costs	$696,463
Federal F&A Costs	$112,131
Approved Budget	$808,594
Federal Share	$808,594
TOTAL FEDERAL AWARD AMOUNT	$808,594
AMOUNT OF THIS ACTION (FEDERAL SHARE)	$808,594

SUMMARY TOTALS FOR ALL YEARS		
YR	**THIS AWARD**	**CUMULATIVE TOTALS**
33	$808,594	$808,594

Fiscal Information:

CFDA Number:	93.393
EIN:	1900210016A1
Document Number:	UCA033193H

PMS Account Type:	B (Subaccount)
Fiscal Year:	2014

IC	CAN	2014
CA	8479565	$808,594

NIH Administrative Data:
PCC: Y7DC / **OC**: 414P / **Released**: KEARSEJ 09/03/2014
Award Processed: 05/08/2014 01:52:21 PM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5U01CA033193-33

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

SECTION III – TERMS AND CONDITIONS – 5U01CA033193-33

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

a. The grant program legislation and program regulation cited in this Notice of Award.
b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) U01CA033193. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov/.

This award represents the final year of the competitive segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: http://grants.nih.gov/grants/policy/policy.htm#gps .

A final Federal Financial Report (FFR) (SF 425) must be submitted through the eRA Commons (Commons) within 90 days of the expiration date; see the NIH Grants Policy Statement Section 8.6.1 Financial Reports, http://grants.nih.gov/grants/policy/policy.htm#gps, for additional information on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System's (PMS) cash transaction data.

A Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 90 days of the expiration date. The HHS 568 form may be downloaded at: http://grants.nih.gov/grants/forms.htm.

Unless an application for competitive renewal is submitted, a final progress report must also be submitted within 90 days of the expiration date. Instructions for preparing a Final Progress Report are at: http://grants.nih.gov/grants/funding/finalprogressreport.pdf. Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the final progress report. Institute/Centers may accept the progress report contained in competitive renewal (type 2) in lieu of a separate final progress report. Contact the awarding IC for IC-specific policy regarding acceptance of a progress report contained in a competitive renewal application in lieu of a separate final progress report.

NIH **strongly encourages** electronic submission of the final progress report and the final invention statement through the Closeout feature in the Commons, but will accept an email or hard copy submission as indicated below.

Email: The final progress report and final invention statement may be e-mailed as PDF attachments to the NIH Central Closeout Center at: NIHCloseoutCenter@mail.nih.gov.

Hard copy: Paper submissions of the final progress report and the final invention statement may be faxed to the NIH Division of Central Grants Processing at 301-480-2304, or mailed to:

NIH Division of Central Grants Processing, OER
6705 Rockledge Drive
Suite 5016, Room 5109

MSC 7986
Bethesda, MD 20892-7986 (for regular or U.S. Postal Service Express mail)
Bethesda, MD 20817 (for other courier/express mail delivery only)

NOTE: If this is the final year of a competitive segment due to the transfer of the grant to another institution, then a Final Progress Report is not required. However, a final FFR is required and should be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required and should be sent directly to the assigned Grants Management Specialist.

Treatment of Program Income:
Additional Costs

SECTION IV – CA Special Terms and Conditions – 5U01CA033193-33

RESTRICTION: This award is issued in accordance with the discussion between Joy Kearse of the National Cancer Institute and Olaf Kelm on 9/3/14. Funds awarded are contingent on receipt and approval by the National Institutes of Health of the 31-year Federal Financial Report (FFR) within 60 days (11/3/14) of the issue date of this award 9/4/14. If an acceptable FFR is not received within the 60 day period, cash disbursement may be suspended and/or this grant may be terminated.

REQUIREMENT: This award is issued as a cooperative agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the Terms and Conditions of Award below, which are hereby incorporated by reference as special terms and conditions of this award.

These special Terms and Conditions of Award are in addition to and not in lieu of otherwise applicable OMB administrative guidelines, Federal Regulations, including HHS Grant Administration Regulations at 42 CFR Part 52, 45 CFR Parts 74 and 92, and other HHS, PHS, and NIH Grant Administration policy statements.

Collaborative Terms of Award

Nature of Collaboration with NCI Staff
NCI has certain responsibilities in terms of this cooperative agreement which involve assistance, information support, and scientific collaboration.

1. Scientific Resource
Since the monographs on each chemical which appear in the columns published by IARC are fundamentally an international information resource and data bank on carcinogenesis and evaluation of qualitative risk of chemicals to human, NCI, in an assistance and cooperative role, provides information and data which assist IARC staff in the preparation of certain sections of the final monograph (Sections 1.1 to 2.3). Sections 3.1 to 4.3 are developed by the Working Groups which consist of international scientists who review all these documents at the time of the meetings (3 per year) in Lyon, France. The National Cancer Institute, through arrangements with a contractor will provide such assistance.

2. Planning for Meetings of the Working Group
The IARC project is one of international support with NCI being the USA supporter for the monograph and the Information Bulletins on the Survey of Chemicals Being Tested for Carcinogenicity. This bulletin is a listing of chemicals being tested in laboratories throughout the world. Under the Cooperative Agreement, NCI:

a. Makes suggestions to IARC on types of chemicals that should be evaluated at the three planned working group meetings per held in Lyon, France.

b. Makes suggestions and gives assistance to IARC as to USA resource people who should attend and participate in Working Group meetings. Personnel from regulatory agencies and trade

associations should attend as observers.

3. Program Involvement in Relation to Input from NCI
Under the section on scientific resources, reference was made to NCI input as to data on production , occurrence, analysis, and use of chemicals. NCI, also provides information relevant to carcinogenicity on chemicals tested in U.S. laboratories. These data are then incorporated in the Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity.

In discussing certain phases of work that involve assistance and collaboration on the part of NCI with IARC, reference was made to the essentiality of effective liaison and support. Participation by the NCI Program Director in the working group meetings in Lyon, France could be either as an observer or as a representative of NCI or as a full member of the working group in his personal capacity as a scientist.

4. Reporting Requirements
NCI wishes to continue a semi-annual reporting requirement with scheduling or due dates for reports worked out by mutual agreement between NCI staff and the IARC principal investigators. The volumes of monographs, supplements and survey bulletins are actually exhibits of achievements and accomplishment. Consequently, the semi-annual reports should dwell on planning, participation, selection of chemicals, problems of interfacing and cooperation and logistical matters. In addition, an annual report to be included in the required continuation applications should reflect that the project continues to conform to the purposes, objectives and conditions of the award and has substantial programmatic involvement by NCI with the performer of the project.

5. Publication and Distribution
One of the significant features of the IARC project in development of this international authoritative reference source is the publication and distribution, on a world-wide basis, of these volumes, including the supplements to the volumes listing Chemicals and Industrial Processes Associated with Cancer in Humans, as well as the Survey Bulletins.

The National Cancer Institute will receive approximately 400 copies of each volume published. The NCI distributes these copies to NCI staff, representatives of other agencies interested in environmental and occupational carcinogenesis, selected university scientist engaged in carcinogenesis research, public health organizations and medical libraries. Therefore, many organizations and scientists in the USA and abroad benefit from this program, which is partially supported by the National Cancer Institute.

The following administrative terms also apply:

REQUIREMENT: If a renewal application is submitted for this project, the requested budget is subject to the direct cost cap calculated in accordance with the National Cancer Institute's (NCI) policy, "Policy for Allowable Requested Budget Levels of Renewal (Type 2) R01, U01 and P01 Applications." This policy was announced in the NIH Guide for Grants and Contracts on August 15, 2008 and can be found at: http://grants.nih.gov/grants/guide/notice-files/NOT-CA-08-026.html

INFORMATION: In accordance with the National Cancer Institute's (NCI's) Fiscal Year (FY) 2014 funding policies for non-competing awards, this award has been issued at 97% of the support recommended for this year on last year's Notice of Award. Information on NIH's Funding Policies for FY 2014 is available at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-055.html

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Joy Kearse
Email: kearsej@mail.nih.gov **Phone**: 301-631-3002 **Fax**: 301-451-5391

Program Official: Ronald L Johnson
Email: rjohnso2@mail.nih.gov **Phone**: 240-276-6190

SPREADSHEET SUMMARY
GRANT NUMBER: 5U01CA033193-33

INSTITUTION: INTERNATIONAL AGENCY FOR RES ON CANCER

Budget	Year 33
Salaries and Wages	$381,055
Fringe Benefits	$127,020
Consultant Services	$40,829
Travel Costs	$2,203
Other Costs	$145,356
TOTAL FEDERAL DC	$696,463
TOTAL FEDERAL F&A	$112,131
TOTAL COST	$808,594

Facilities and Administrative Costs	Year 33
F&A Cost Rate 1	16.1%
F&A Cost Base 1	$696,463
F&A Costs 1	$112,131

RESEARCH PROJECT COOPERATIVE AGREEMENT **Federal Award Date:** 06/05/2015

Department of Health and Human Services
National Institutes of Health
NATIONAL CANCER INSTITUTE

Grant Number: 5U01CA033193-33 REVISED
FAIN: U01CA033193

Principal Investigator(s):
Kurt Straif

Project Title: Evaluation of Carcinogenic Risks to Humans

INTERNATIONAL AGENCY-RES CANCER
150 COURS ALBERT THOMAS
F-69372 LYON CEDEX 08, FRANCE,
FRA

Award e-mailed to: igo@iarc.fr

Period Of Performance:
Budget Period: 09/01/2014 – 08/31/2015
Project Period: 09/01/1985 – 08/31/2015

Dear Business Official:

The National Institutes of Health hereby revises this award (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to INTERNATIONAL AGENCY FOR RES ON CANCER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number U01CA033193. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Joy Kearse
Grants Management Officer
NATIONAL CANCER INSTITUTE

Additional information follows

SECTION I – AWARD DATA – 5U01CA033193-33 REVISED

Award Calculation (U.S. Dollars)

Salaries and Wages	$381,055
Fringe Benefits	$127,020
Personnel Costs (Subtotal)	$508,075
Consultant Services	$40,829
Travel Costs	$2,203
Other Costs	$145,356
Federal Direct Costs	$696,463
Federal F&A Costs	$112,131
Approved Budget	$808,594
Total Amount of Federal Funds Obligated (Federal Share)	$808,594
TOTAL FEDERAL AWARD AMOUNT	$808,594
AMOUNT OF THIS ACTION (FEDERAL SHARE)	$0

SUMMARY TOTALS FOR ALL YEARS		
YR	**THIS AWARD**	**CUMULATIVE TOTALS**
33	$808,594	$808,594

Fiscal Information:

CFDA Name: Cancer Cause and Prevention Research
CFDA Number: 93.393
EIN: 1900210016A1
Document Number: UCA033193H
PMS Account Type: B (Subaccount)
Fiscal Year: 2014

IC	CAN	2014
CA	8479565	$808,594

NIH Administrative Data:
PCC: Y7DC / **OC**: 414P / **Released**: KEARSEJ 06/04/2015
Award Processed: 03/23/2015 01:36:12 PM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5U01CA033193-33 REVISED

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

SECTION III – TERMS AND CONDITIONS – 5U01CA033193-33 REVISED

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

a. The grant program legislation and program regulation cited in this Notice of Award.
b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
c. 45 CFR Part 75 or as applicable 45 CFR Part 74 or 45 CFR Part 92.
d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) U01CA033193. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov/.

This award represents the final year of the competitive segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: http://grants.nih.gov/grants/policy/policy.htm#gps.

A final expenditure Federal Financial Report (FFR) (SF 425) must be submitted through the eRA Commons (Commons) within 120 days of the expiration date; see the NIH Grants Policy Statement Section 8.6.1 Financial Reports, http://grants.nih.gov/grants/policy/policy.htm#gps, for additional information on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System's (PMS) quarterly cash transaction data. A final quarterly federal cash transaction report is not required for awards in PMS B subaccounts (i.e., awards to foreign entities and to Federal agencies). NIH will close the awards using the last recorded cash drawdown level in PMS for awards that do not require a final FFR on expenditures or quarterly federal cash transaction reporting. It is important to note that for financial closeout, if a grantee fails to submit a required final expenditure FFR, NIH will close the grant using the last recorded cash drawdown level. If the grantee submits a final expenditure FFR but does not reconcile any discrepancies between expenditures reported on the final expenditure FFR and the last cash report to PMS, NIH will close the award at the lower amount. This could be considered a debt or result in disallowed costs.

A Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 120 days of the expiration date. The HHS 568 form may be downloaded at: http://grants.nih.gov/grants/forms.htm. This paragraph does not apply to Training grants, Fellowships, and certain other programs—i.e., activity codes C06, R13, R25, S10.

Unless an application for competitive renewal is submitted, a final progress report must also be submitted within 120 days of the expiration date. Instructions for preparing a Final Progress Report are at: http://grants.nih.gov/grants/funding/finalprogressreport.pdf. Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the final progress report. Institute/Centers may accept the progress report contained in competitive renewal (type 2) in lieu of a separate final progress report. Contact the awarding IC for IC-specific policy regarding acceptance of a progress report contained in a competitive renewal application in lieu of a separate final progress report.

NIH strongly encourages electronic submission of the final progress report and the final invention statement through the Closeout feature in the Commons, but will accept an email or hard copy submission as indicated below.

Email: The final progress report and final invention statement may be e-mailed as PDF attachments to: NIHCloseoutCenter@mail.nih.gov.

Hard copy: Paper submissions of the final progress report and the final invention statement may be faxed to the NIH Division of Central Grants Processing, Grants Closeout Center, at 301-480-2304, or mailed to:

National Institutes of Health
Office of Extramural Research
Division of Central Grants Processing
Grants Closeout Center
6705 Rockledge Drive
Suite 5016, MSC 7986
Bethesda, MD 20892-7986 (for regular or U.S. Postal Service Express mail)
Bethesda, MD 20817 (for other courier/express deliveries only)

NOTE: If this is the final year of a competitive segment due to the transfer of the grant to another institution, then a Final Progress Report is not required. However, a final expenditure FFR is required and should be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required and should be sent directly to the assigned Grants Management Specialist.

Treatment of Program Income:
Additional Costs

SECTION IV – CA Special Terms and Conditions – 5U01CA033193-33 REVISED

INFORMATION: This award reflects the National Cancer Institute's review and approval of the 31-year Federal Financial Report (FFR), and removes the restriction on the prior Notice of Award dated 9/4/14.

THE FOLLOWING TERMS FROM THE PREVIOUS NOTICE OF GRANT AWARD ISSUED ON 9/4/14 ALSO APPLY TO THIS AWARD:

REQUIREMENT: This award is issued as a cooperative agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the Terms and Conditions of Award below, which are hereby incorporated by reference as special terms and conditions of this award.

These special Terms and Conditions of Award are in addition to and not in lieu of otherwise applicable OMB administrative guidelines, Federal Regulations, including HHS Grant Administration Regulations at 42 CFR Part 52, 45 CFR Parts 74 and 92, and other HHS, PHS, and NIH Grant Administration policy statements.

Collaborative Terms of Award

Nature of Collaboration with NCI Staff
NCI has certain responsibilities in terms of this cooperative agreement which involve assistance, information support, and scientific collaboration.

1. Scientific Resource
Since the monographs on each chemical which appear in the columns published by IARC are

fundamentally an international information resource and data bank on carcinogenesis and evaluation of qualitative risk of chemicals to human, NCI, in an assistance and cooperative role, provides information and data which assist IARC staff in the preparation of certain sections of the final monograph (Sections 1.1 to 2.3). Sections 3.1 to 4.3 are developed by the Working Groups which consist of international scientists who review all these documents at the time of the meetings (3 per year) in Lyon, France. The National Cancer Institute, through arrangements with a contractor will provide such assistance.

2. Planning for Meetings of the Working Group
The IARC project is one of international support with NCI being the USA supporter for the monograph and the Information Bulletins on the Survey of Chemicals Being Tested for Carcinogenicity. This bulletin is a listing of chemicals being tested in laboratories throughout the world. Under the Cooperative Agreement, NCI:

a. Makes suggestions to IARC on types of chemicals that should be evaluated at the three planned working group meetings per held in Lyon, France.

b. Makes suggestions and gives assistance to IARC as to USA resource people who should attend and participate in Working Group meetings. Personnel from regulatory agencies and trade associations should attend as observers.

3. Program Involvement in Relation to Input from NCI
Under the section on scientific resources, reference was made to NCI input as to data on production , occurrence, analysis, and use of chemicals. NCI, also provides information relevant to carcinogenicity on chemicals tested in U.S. laboratories. These data are then incorporated in the Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity.

In discussing certain phases of work that involve assistance and collaboration on the part of NCI with IARC, reference was made to the essentiality of effective liaison and support. Participation by the NCI Program Director in the working group meetings in Lyon, France could be either as an observer or as a representative of NCI or as a full member of the working group in his personal capacity as a scientist.

4. Reporting Requirements
NCI wishes to continue a semi-annual reporting requirement with scheduling or due dates for reports worked out by mutual agreement between NCI staff and the IARC principal investigators. The volumes of monographs, supplements and survey bulletins are actually exhibits of achievements and accomplishment. Consequently, the semi-annual reports should dwell on planning, participation, selection of chemicals, problems of interfacing and cooperation and logistical matters. In addition, an annual report to be included in the required continuation applications should reflect that the project continues to conform to the purposes, objectives and conditions of the award and has substantial programmatic involvement by NCI with the performer of the project.

5. Publication and Distribution
One of the significant features of the IARC project in development of this international authoritative reference source is the publication and distribution, on a world-wide basis, of these volumes, including the supplements to the volumes listing Chemicals and Industrial Processes Associated with Cancer in Humans, as well as the Survey Bulletins.

The National Cancer Institute will receive approximately 400 copies of each volume published. The NCI distributes these copies to NCI staff, representatives of other agencies interested in environmental and occupational carcinogenesis, selected university scientist engaged in carcinogenesis research, public health organizations and medical libraries. Therefore, many organizations and scientists in the USA and abroad benefit from this program, which is partially supported by the National Cancer Institute.

The following administrative terms also apply:

REQUIREMENT: If a renewal application is submitted for this project, the requested budget is subject to the direct cost cap calculated in accordance with the National Cancer Institute's (NCI) policy, "Policy for Allowable Requested Budget Levels of Renewal (Type 2) R01, U01 and P01

Applications." This policy was announced in the NIH Guide for Grants and Contracts on August 15, 2008 and can be found at: http://grants.nih.gov/grants/guide/notice-files/NOT-CA-08-026.html

INFORMATION: In accordance with the National Cancer Institute's (NCI's) Fiscal Year (FY) 2014 funding policies for non-competing awards, this award has been issued at 97% of the support recommended for this year on last year's Notice of Award. Information on NIH's Funding Policies for FY 2014 is available at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-055.html

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Joy Kearse
Email: kearsej@mail.nih.gov **Phone**: 301-631-3002 **Fax**: 301-451-5391

Program Official: Ronald L Johnson
Email: rjohnso2@mail.nih.gov **Phone**: 240-276-6190

SPREADSHEET SUMMARY
GRANT NUMBER: 5U01CA033193-33 REVISED

INSTITUTION: INTERNATIONAL AGENCY FOR RES ON CANCER

Budget	Year 33
Salaries and Wages	$381,055
Fringe Benefits	$127,020
Personnel Costs (Subtotal)	$508,075
Consultant Services	$40,829
Travel Costs	$2,203
Other Costs	$145,356
TOTAL FEDERAL DC	$696,463
TOTAL FEDERAL F&A	$112,131
TOTAL COST	$808,594

Facilities and Administrative Costs	Year 33
F&A Cost Rate 1	16.1%
F&A Cost Base 1	$696,463
F&A Costs 1	$112,131

Progress Report Scanning Cover Sheet

5U01CA033193-33

PI Name:	**STRAIF, KURT**
Org:	**INTERNATIONAL AGENCY FOR RES ON CANCER**
Start Date:	**09/01/2014**
Snap:	**N/A** (NEEDS TO BE BOOKMARKED)
Appl ID:	**8732603**
Rec'd Date:	**06/25/2014**

Form Approved Through 08/31/2015

OMB No. 0925-0002

Department of Health and Human Services
Public Health Services

Grant Progress Report

Review Group	Type	Activity	Grant Number
ZCA1RPRB7J1	5	U01	4U01CA033193-~~02~~ 33

Total Project Period
From: 09/01/1985 Through: 08/31/2015

Requested Budget Period
From: 09/01/2014 Through: 08/31/2015

1. TITLE OF PROJECT
Evaluation of Carcinogenic Risks to Humans

2a. PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR
(Name and address, street, city, state, zip code)
Kurt Straif
IARC Monographs Section
International Agency for Research on Cancer
150, Cours Albert Thomas
F-69372 Lyon cedex 08, France

2b. E-MAIL ADDRESS
imo@iarc.fr

2c. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT
IARC Monographs Section

2d. MAJOR SUBDIVISION
IARC Monographs Section

2e. Tel: 33-4-72.73.85.07 Fax: 33-4-72.73.83.19

3a. APPLICANT ORGANIZATION
(Name and address, street, city, state, zip code)
International Agency for Research on Cancer
150, Cours Albert Thomas
F-69372 Lyon cedex 08, France

3b. Tel: 33-4-72.73.84.85 Fax: 33-4-72.73.85.75

3c. DUNS: 279551881

4. ENTITY IDENTIFICATION NUMBER
1900210016A1

6. HUMAN SUBJECTS ☒ No ☐ Yes

6a. Research Exempt	If Exempt ("Yes" in 6a): Exemption No.	If Not Exempt ("No" in 6a): IRB approval date
☐ No ☐ Yes		

6b. Federal Wide Assurance No. 00005058

6c. NIH-Defined Phase III Clinical Trial ☒ No ☐ Yes

5. NAME, TITLE AND ADDRESS OF ADMINISTRATIVE OFFICIAL
Olaf Kelm, External Relations Officer, International Agency for Research on Cancer, 150 Cours Albert Thomas, F-69372 Lyon cedex 08, France

Tel: 33-4-72.73.84.94 Fax: 33-4-72.73.85.64

E-MAIL: igo@iarc.fr

7. VERTEBRATE ANIMALS ☒ No ☐ Yes

7a. If "Yes," IACUC approval Date

7b. Animal Welfare Assurance No.

10. PROJECT/PERFORMANCE SITE(S)

Organizational Name: Applicant

DUNS:

8. COSTS REQUESTED FOR NEXT BUDGET PERIOD

8a. DIRECT $718,004 8b. TOTAL $833,603

Street 1:

Street 2:

9. INVENTIONS AND PATENTS ☒ No ☐ Yes

If "Yes, ☐ Previously Reported
☐ Not Previously Reported

City:	County:
State:	Province:
Country:	Zip/Postal Code:

Congressional Districts:

11. NAME AND TITLE OF OFFICIAL SIGNING FOR APPLICANT ORGANIZATION *(Item 13)*
Dr Christopher P. Wild, Director

TEL: 33-4-72.73.85.77 FAX: 33-4-72.73.85.64 E-MAIL: director@iarc.fr

12. Corrections to Page 1 Face Page

13. APPLICANT ORGANIZATION CERTIFICATION AND ACCEPTANCE: I certify that the statements herein are true, complete and accurate to the best of my knowledge, and accept the obligation to comply with Public Health Services terms and conditions if a grant is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties.

SIGNATURE OF OFFICIAL NAMED IN 11. *(In ink)*

DATE
19 June 2014

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

DETAILED BUDGET FOR NEXT BUDGET PERIOD – DIRECT COSTS ONLY	FROM 09/01/2014	THROUGH 08/31/2015	GRANT NUMBER 4U01CA033193-32

List PERSONNEL *(Applicant organization only)*
Use Cal, Acad, or Summer to Enter Months Devoted to Project
Enter Dollar Amounts Requested *(omit cents)* for Salary Requested and Fringe Benefits

NAME	ROLE ON PROJECT	Cal. Mnths	Acad. Mnths	Summer Mnths	SALARY REQUESTED	FRINGE BENEFITS	TOTALS
STRAIF, K.	PD/PI	(b)(4), (b)(6) [redacted]			0	0	0
EL-GHISSASSI, F.* (see note 1 on page 3)	Scientist	[redacted]			90,538	30,179	120,717
BENBRAHIM-TALLAA, L.*	Scientist	[redacted]			100,928	33,642	134,570
BOUVARD, V.*	Scientist	[redacted]			100,232	33,410	133,642
MATTOCK, H.	Editor	[redacted]			78,589	26,196	104,785
EGRAZ, S.	Archivist	[redacted]			50,337	16,779	67,116
To be named** (see notes 1 & 2 on p. 3)	Typist	12			25,989	8,663	34,652
SUBTOTALS →					446,613	148,869	595,482

CONSULTANT COSTS	
EQUIPMENT *(Itemize)*	
SUPPLIES *(Itemize by category)*	
TRAVEL One trip of PI to USA for a scientific meeting and to consult with NCI program officials	2,100
INPATIENT CARE COSTS	
OUTPATIENT CARE COSTS	
ALTERATIONS AND RENOVATIONS *(Itemize by category)*	
OTHER EXPENSES *(Itemize by category)* See page 3	120,422
SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD	$ 718,004
CONSORTIUM/CONTRACTUAL COSTS — DIRECT COSTS	
CONSORTIUM/CONTRACTUAL COSTS — FACILITIES AND ADMINISTRATIVE COSTS	
TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD *(Item 8a, Face Page)*	$ 718,004

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

BUDGET JUSTIFICATION	GRANT NUMBER 4U01CA033193-32

Provide a detailed budget justification for those line items and amounts that represent a significant change from that previously recommended. Use continuation pages if necessary.

OTHER:

- Monograph Working Group Volume 111 (Oct-14)	$ 49,711
- Monograph Working Group Volume 112 (Mar-15)	$ 49,711
- Printing of Monographs Volume ($20,000 X 1)	$ 20,000
- Books, journals and reproduction costs	$ 1,000
	$120,422

Note 1 to detailed budget: only [redacted] out of the 12 Calendar months devoted to the project are anticipated to be charged to the grant.
Note 2 to detailed budget: only [redacted]% of Typist's post is anticipated to be charged to the grant (recruitment on-going).

CURRENT BUDGET PERIOD	FROM 09/01/2013	THROUGH 08/31/2014

Explain any estimated unobligated balance (including prior year carryover) that is greater than 25% of the current year's total budget.

	Total estimated expenditure	Estimated unobligated balance
DIRECT COSTS	$674,922	$0
INDIRECT COSTS	$108,662	$0
TOTAL COSTS	$783,584	$0

Program Director/Principal Investigator: STRAIF, Kurt
(Last, first, middle)

For New and Renewal Applications (PHS 398) – DO NOT SUBMIT UNLESS REQUESTED
For Non-competing Progress Reports (PHS 2590) – Submit only Active Support for Key Personnel

PHS 398/2590 OTHER SUPPORT

Provide active support for all key personnel. **Other Support includes all financial resources, whether Federal, non-Federal, commercial or institutional, available in direct support of an individual's research endeavors, including but not limited to research grants, cooperative agreements, contracts, and/or institutional awards.** Training awards, prizes, or gifts do not need to be included.

There is no "form page" for other support. Information on other support should be provided in the *format* shown below, using continuation pages as necessary. ***Include the principal investigator's name at the top and number consecutively with the rest of the application.*** The sample below is intended to provide guidance regarding the type and extent of information requested.
For instructions and information pertaining to the use of and policy for other support, see Other Support in the PHS 398 Part III, Policies, Assurances, Definitions, and Other Information.
Note effort devoted to projects must now be measured using person months. Indicate calendar, academic, and/or summer months associated with each project.

Format

NAME OF INDIVIDUAL
ACTIVE/PENDING

Project Number (Principal Investigator) Source Title of Project *(or Subproject)* The major goals of this project are...	Dates of Approved/Proposed Project Annual Direct Costs	Person Months (Cal/Academic/ Summer)

OVERLAP *(summarized for each individual)*

LAUBY-SECRETAN, B.
ACTIVE
VS/2013/0212 (Lauby-Secretan) 1/1/2013 – 12/31/2013 (b)(4), (b) calendar
European Commission 53,100 euros D.C. ($73,040)
IARC Monographs Programme 2013
The major goals of this project are to support, in part, a third volume of IARC Monographs each year.

STRAIF, K.
ACTIVE
N/A (Straif) 1/1/2013 – 09/30/2014 (b)(4), (b)(6) calendar
NIH/NIEHS/National Toxicology Program $88,496 euros D.C.
IARC Monographs Program 2013
The major goal of this project is to help support the Monographs program and its scientific activities.

LAUBY-SECRETAN, B.
PENDING
(b)(4), (b)(6)
[redacted]

OVERLAP
None.

LOOMIS, D.; BENBRAHIM-TALLAA, L.; BOUVARD, V.; EL-GHISSASSI, F. ; GROSSE, Y.; GUHA, N. ; GUYTON, K.; MATTOCK, H.
There are no other active or pending sources of support for the key scientists on the IARC Monographs project.

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

PROGRESS REPORT SUMMARY	GRANT NUMBER 4U01CA033193-32	
	PERIOD COVERED BY THIS REPORT	
PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR STRAIF, Kurt	FROM 1 September 2013	THROUGH 31 August 2014

APPLICANT ORGANIZATION
International Agency for Research on Cancer

TITLE OF PROJECT (Repeat title shown in Item 1 on first page)
Evaluation of Carcinogenic Risks to Humans

A. Human Subjects (Complete Item 6 on the Face Page)		
Involvement of Human Subjects	☒ No Change Since Previous Submission	☐ Change
B. Vertebrate Animals (Complete Item 7 on the Face Page)		
Use of Vertebrate Animals	☒ No Change Since Previous Submission	☐ Change
C. Select Agent Research	☒ No Change Since Previous Submission	☐ Change
D. Multiple PD/PI Leadership Plan	☒ No Change Since Previous Submission	☐ Change
E. Human Embryonic Stem Cell Line(s) Used	☒ No Change Since Previous Submission	☐ Change

SEE PHS 2590 INSTRUCTIONS.

WOMEN AND MINORITY INCLUSION: See PHS 398 Instructions. Use Inclusion Enrollment Report Format Page and, if necessary, Targeted/Planned Enrollment Format Page.

A. Specific Aims

The aim of the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans is to critically review and evaluate the published scientific evidence on carcinogenic hazards to which humans are exposed. These include chemicals, complex mixtures, physical agents, biological agents, occupational exposures, and personal habits. International, interdisciplinary Working Groups (WG) of expert scientists develop the critical reviews and evaluations, which are published in the IARC Monographs series.

B. Studies and Results

IARC convened two Monograph meetings to develop Vol. 109-110 and two Advisory Groups, one on Quantiative Risk Characterization and one on Priorities for the IARC Mongraphs during 205-2019. Volumes 101-103 have been published and Vol. 104-106 have been published on-line.

Volume 109: Outdoor Air Pollution (8-15 October 2013)

In October 2013, a working group reviewed the carcinogenicity of outdoor air pollution. Outdoor air pollution and particulate matter from outdoor air pollution were both classified as carcinogenic to humans (IARC Group 1), based on sufficient evidence of carcinogenicity in humans and experimental animals and strong mechanistic evidence. Exposure to outdoor air pollution as measured be several indicators, including the concentrations of pollutants in the air and measures of exposure to traffic, is associated with increased risk of lung cancer. The Working Group also found limited evidence that outdoor air pollution causes bladder cancer, based on positive associations in a number of epidemiologic studies (Loomis et al., 2013).

Advisory Group on Quantitative Risk Characterization (18-19 November 2013)

The IARC Monographs convened an Advisory Group (AG) to Recommend on Quantitative Risk Characterization. The AG encouraged IARC to develop approaches for conducting exposure-response analyses in conjunction with Monographs by developing improved methods of capturing exposure and risk data, and standardizing approaches to exposure-response analysis; to promote the estimation of the global

burden of disease associated with high-priority carcinogens in collaboration with other IARC sections. The AG recognized that full implementation of these recommendations would require additional resources to assure that the established programme of hazard identification is not compromised.

Advisory Group on Priorities for the IARC Monographs during 2015-2019 (7-9 April 2014)
The IARC Monographs convened an Advisory Group (AG) to recommend evaluation topics for 2015-2019 and to discuss strategic matters for the IARC Monographs programme. The AG considered responses to a call for nominations and recommended a broad range of agents and exposures with high or medium priority. Additionally, the AG endorsed the current system of expert reviews with strict management of conflict of interests; encouraged the Secretariat to explore the use of systematic review tools to further increase transparency and efficiency; supported recent recommendations of a separate AG on Quantitative Risk Characterization; recognized the need for systematic identification of mechanistic data, with transparent selection of publications, to focus on clear elucidation of mechanistic processes; recommended exploration of additional opportunities to address cancer risk within low and medium-income countries.

Volume 110: Perfluoro-octanoic acid, tetrafluoroethylene, dichlorimethane, 1,2-dichloripropane, and 1,3-propane sultone (3-10 June 2014)
In June 2014, a Working Group (WG) reviewed the carcinogenicity of five chemicals. Perfluoro-octanoic acid (PFOA) was classified as possibly carcinogenic to humans (Group 2B), based on limited evidence in humans that exposure to PFOA is associated with testes and kidney cancer and limited evidence in experimental animals. Tetrafluoroethylene was upgraded from possibly carcinogenic to humans (Group 2B) to probably carcinogenic to humans (Group 2A), based on inadequate evidence in humans and sufficient evidence in experimental animals with unusual results (neoplasms at multiple sites and with very high incidence observed in exposed rodents of both sexes, including liver haemangiosarcoma, hepatocellular carcinoma, and histocytic sarcoma, in mice; renal cell adenoma or carcinoma (combined), hepatocellular carcinoma, mononuclear cell leukaemia, and the rare liver haemangiosarcoma in female rats). Dichloromethane (DCM) was classified as probably carcinogenic to humans (Group 2A), based on limited evidence in humans that DCM use is associated with biliary tract cancer and non-Hodgkin lymphoma and sufficient evidence in experimental animals. 1,2-dichloropropane (1,2-DCP) was classified as carcinogenic to humans (Group 1), based on sufficient evidence in humans that exposure to 1,2-DCP causes cancer of the biliary tract in exposed workers and sufficient evidence in experimental animals. 1,3-Propane sultone was classified as probably carcinogenic to humans (Group 2A), based on inadequate evidence in humans and sufficient evidence in experimental animals with a mechanistic upgrade supported by a strong evidence for genotoxicity.

The full text of all *Monographs* is available free of charge on http://monographs.iarc.fr/. All volumes published since Vol. 1 (1972) and Supplements 1, 4 and 7 are available. The Lancet Oncology summaries are also freely available.

D. Plans. During the next budget period, IARC will convene three Monograph Working Groups:
Vol. 111: Some nano-materials and some fibres, 30 Sept.-7 Oct. 2014
Vol. 112: Some pesticides and related chemicals, 3-10 March 2015
Vol. 113: Agents to be announced soon at http://monographs.iarc.fr/ENG/Meetings/index.php, 2-9 June 2015

IARC will also focus attention on checking Vol. 107-112 and preparing them for publication and will continue making the full text of all Monographs freely available. Further dissemination improvements will include: a) completion of a fully searchable relational database of Monograph results, enabling complex queries, and linking to other IARC databases (IARC Blue Books, Globocan, etc); with administrative supplement to this grant, develop a link on the IARC web-pages to access NCI grants relevant to a given agent; b) development of ePub format of Monographs for delivery to e-book readers and tablets.

Benbrahim-Tallaa L, Lauby-Secretan B, Loomis D, Guyton K, Grosse Y, El Ghissassi F, Bouvard V, Guha N, Mattock, Straif K, on behalf of the International Agency for Research on Cancer Monograph Working Group, Lyon, France. The carcinogenicity of pefluoro-octanoic acid, tetrafluoroethylene, dichloromethane, 1,2-dichloropropane, and 1,3-propane sultone. Lancet Oncol. 2014 (in press; will be immediately available free of charge on the Lancet Oncology website)

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 101, Some Chemicals Present in Industrial and Consumer Products, Food and Drinking-water. IARC, Lyon. (available free of charge): http://monographs.iarc.fr/ENG/Monographs/vol101/index.php

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 102, Non-Ionizing Radiation, Part 2: Radiofrequency Electromagnetic Fields. IARC, Lyon. (available free of charge): http://monographs.iarc.fr/ENG/Monographs/vol102/index.php

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 103, Bitumen and bitumen fumes, and some heterocyclic polycyclic aromatic hydrocarbons. IARC, Lyon. (available free of charge): http://monographs.iarc.fr/ENG/Monographs/vol103/index.php

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 104, Malaria and Some Polyomaviruses (SV40, BK, JC, and Merkel Cell Viruses). IARC, Lyon. Published on-line (available free of charge): http://monographs.iarc.fr/ENG/Monographs/vol104/index.php

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 105, Diesel and Gasoline Engine Exhausts and Some Nitroarenes. IARC, Lyon. Published on-line (available free of charge): http://monographs.iarc.fr/ENG/Monographs/vol105/index.php

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 106, Trichloroethylene, Tetrachloroethylene and Some Other Chlorinated Agents. IARC, Lyon. Published on-line (available free of charge): http://monographs.iarc.fr/ENG/Monographs/vol106/index.php

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Report of the IARC Advisory Group to Recommend on Quantitative Risk Characterization, 18-19 November 2013. IARC Internal report 14/001, Lyon, France 2014: http://monographs.iarc.fr/ENG/Publications/internrep/14-001.pdf

Loomis D, Huang W, Chen G. The International Agency for Research on Cancer (IARC) evaluation of the carcinogenicity of outdoor air pollution: focus on China. Chin J Cancer 2014 33(4): 189-96. PMID:24694836

Loomis D, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Baan R, Mattock H, Straif K, on behalf of the International Agency for Research on Cancer Monograph Working Group, IARC, Lyon, France. The carcinogenicity of outdoor air pollution. Lancet Oncol. Oct 24, 2013; 14: 1262-1263 PMID: not yet indexed (available free of charge: http://download.thelancet.com/pdfs/journals/lanonc/PIIS147020451370487X.pdf?id=qaav99_SRMYRWhmPFrfyu)

Straif K, Loomis D, Guyton K, Grosse Y, Lauby-Secretan, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Mattock H; International Agency for Research on Cancer Monographs Advisory Group (IARC), Lyon, FrancLe. Future priorities for the IARC Monographs. Lancet Oncol. 2014; 15: 683-684 PMID: not yet indexed (available free of charge: http://download.thelancet.com/pdfs/journals/lanonc/PIIS1470204514701688.pdf?id=qaav99_SRMYRWhmPFrfyu)

Program Director/Principal Investigator (Last, first, middle): STRAIF, Kurt

GRANT NUMBER
4U01CA033193-32

CHECKLIST

1. PROGRAM INCOME ***(See instructions.)***
All applications must indicate whether program income is anticipated during the period(s) for which grant support is requested. If program income is anticipated, use the format below to reflect the amount and source(s).

Budget Period	Anticipated Amount	Source(s)

2. ASSURANCES/CERTIFICATIONS ***(See instructions.)***
In signing the application Face Page, the authorized organizational representative agrees to comply with the policies, assurances and/or certifications listed in the application instructions when applicable. Descriptions of individual assurances/certifications are provided in Part III of the PHS 398, and listed in Part I, 4.1 under Item 14. If unable to certify compliance, where applicable, provide an explanation and place it after the Progress Report (Form Page 5).

3. FACILITIES AND ADMINSTRATIVE (F&A) COSTS
Indicate the applicant organization's most recent F&A cost rate established with the appropriate DHHS Regional Office, or, in the case of for-profit organizations, the rate established with the appropriate PHS Agency Cost Advisory Office.

F&A costs will ***not*** be paid on construction grants, grants to Federal organizations, grants to individuals, and conference grants. Follow any additional instructions provided for Research Career Awards, Institutional National Research Service Awards, Small Business Innovation Research/Small Business Technology Transfer Grants, foreign grants, and specialized grant applications.

☒ DHHS Agreement dated: 08/11/2010 ☐ No Facilities and Administrative Costs Requested.

☐ No DHHS Agreement, but rate established with _____ Date _____

CALCULATION*

Entire proposed budget period: Amount of base $ 718,004 x Rate applied 16.10 % = F&A costs $ 115,599

Add to total direct costs from Form Page 2 and enter new total on Face Page, Item 8b.

*Check appropriate box(es):

☐ Salary and wages base ☐ Modified total direct cost base ☒ Other base *(Explain)*

☐ Off-site, other special rate, or more than one rate involved *(Explain)*

Explanation *(Attach separate sheet, if necessary.)*:

Base is total direct costs.

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

ALL PERSONNEL REPORT

Place this form at the end of the signed original copy of the application. Do not duplicate.

GRANT NUMBER
4U01CA033193-32

Always list the PD/PI(s). In addition, list all other personnel who participated in the project during the current budget period for at least one person month or more, regardless of the source of compensation (a person month equals approximately 160 hours or 8.3% of annualized effort). Use the following abbreviated categories for describing Role on Project:

- **PD/PI**
- **Co-Investigator**
- **Faculty**
- **Postdoctoral (scholar, fellow, or other postdoctoral position)**
- **Technician**
- **Staff Scientist (doctoral level)**
- **Statistician**
- **Graduate Student (research assistant)**
- **Non-student Research Assistant**
- **Undergraduate Student**
- **High School Student**
- **Consultant**
- **Other (please specify)**

If personnel are supported by a Reentry or Diversity Supplement please indicate such after the Role on Project, using the following abbreviations: RS - Reentry Supplement; DS - Diversity Supplement.

Use Cal (calendar), Acad, or Summer to enter months devoted to project.

Commons ID	Name	Degree(s)	SSN (last 4 digits)	Role on Project	DoB (MM /YY)	Cal	Acad	Summer
k.straif	Straif, Kurt	MD, PhD	n/a	Principal Investig.	(b)(6)	(b)(4), (b)(6)		
DLOOMIS	Loomis, Dana	PhD	(b)(6)	Co-Investigator				
	Benbrahim-Tallaa, Lamia	PhD	(b)(6)	Staff Scientist				
	Bouvard, Véronique	PhD	n/a	Staff Scientist				
	Egraz, Sandrine	BA	n/a	Other (Archivist)				
	Elbers, Elisabeth	MA	n/a	Technician				
	El-Ghissassi, Fatiha	PhD	n/a	Staff Scientist				
	Grosse, Yann	PhD	n/a	Staff Scientist				
	Guha, Neela	PhD	(b)	Staff Scientist				
Guytonk	Guyton, Kate	PhD	(b)	Staff Scientist				
	Kajo, Brigitte	n/a	n/a	Other (Archivist)				
	Lauby-Secretan, Béatrice	PhD	n/a	Staff Scientist				
	Leroux, Annick	BA	n/a	Technician				
	Lorenzen-Augros, Helene	BA	n/a	Other (Secretary)				

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

ALL PERSONNEL REPORT

Place this form at the end of the signed original copy of the application. Do not duplicate.

GRANT NUMBER
4U01CA033193-32

Always list the PD/PI(s). In addition, list all other personnel who participated in the project during the current budget period for at least one person month or more, regardless of the source of compensation (a person month equals approximately 160 hours or 8.3% of annualized effort). Use the following abbreviated categories for describing Role on Project:

- **PD/PI**
- **Co-Investigator**
- **Faculty**
- **Postdoctoral (scholar, fellow, or other postdoctoral position)**
- **Technician**
- **Staff Scientist (doctoral level)**
- **Statistician**
- **Graduate Student (research assistant)**
- **Non-student Research Assistant**
- **Undergraduate Student**
- **High School Student**
- **Consultant**
- **Other (please specify)**

If personnel are supported by a Reentry or Diversity Supplement please indicate such after the Role on Project, using the following abbreviations: RS - Reentry Supplement; DS - Diversity Supplement.

Use Cal (calendar), Acad, or Summer to enter months devoted to project.

Commons ID	Name	Degree(s)	SSN (last 4 digits)	Role on Project	DoB (MM /YY)	Cal	Acad	Summer
	Mattock, Heidi	PhD	n/a	Other (Editor)	(b)(6) [redacted]	(b)(4), (b)(6) [redacted]		
	Russell, Dorothy vacant from 08/01/2014, recruitment on-going	BA	n/a	Other (Typist)				

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME	POSITION TITLE
Guyton, Kathryn Z	Scientist Monographs Program, International Agency for Research on Cancer, World Health Organization
eRA COMMONS USER NAME (credential, e.g., agency login) (b) (4) [redacted]	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	MM/YY	FIELD OF STUDY
Johns Hopkins University, Baltimore, MD, USA	BA (cum laude)	06/87	Biology with minor in French
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA	PhD	06/93	Environmental Health Sciences

A. Personal Statement

This multidisciplinary research project aims to support carcinogenic hazard classifications by the IARC Monographs Programme. My qualifications to contribute meaningfully to the proposed work comprise expert technical abilities coupled with exceptional leadership, teamwork and communication skills. My technical strengths include currency with mechanistic toxicology and carcinogenesis, centered in the scientific assessment and classification of carcinogenic substances. This experience includes contributions in carcinogenesis mechanisms to human health risk assessments at the US Environmental Protection Agency. In particular, I was a leader of the tetrachloroethylene assessment completed in February 2012, and contributed to assessments of other prevalent environmental contaminants (including trichloroethylene, trichloroacetic acid, dioxin, chloroprene and carbon tetrachloride). I also served as an invited mechanistic expert on the Volume 106 International Agency for Cancer Research Working Group assessing the cancer risks of trichloroethylene and related chemicals. Additionally, my experience comprises advancement of methods to apply mechanistic, genomic, and other high-throughput and high-content data streams in carcinogen classification. Prior work involved providing expertise in molecular toxicology and carcinogenesis to the US National Cancer Institute for projects in the screening, prevention, treatment and imaging of cancer in at-risk populations. With this experience as background, I am well-qualified to provide input to this project. Indeed, I have a strong record of successfully completing quality written work products, including highly cited and influential scientific publications (with numerous articles cited >100 times and an overall *h*-index of 24). In summary, I have a demonstrated record of contributing to and completing high-impact projects in the area of mechanistic data interpretation and carcinogen classification that will benefit this research project.

B. Positions and Honors

Positions and Employment

1993-1997 Research Fellow, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
1997-1999 Scientist, CCS Associates (http://www.ccsainc.com), Vienna, VA, USA
1999-2000 Senior Scientist, CCS Associates, Vienna, VA, USA
2000-2005 Director, Scientific Affairs, CCS Associates, Vienna, VA, USA
2005-2013 Toxicologist, National Center for Environmental Assessment, Office of Research and Development, US Environmental Protection Agency (US EPA), Washington DC, USA
5-12/2012 Acting Deputy National Program Director, Human Health Risk Assessment Research Program, Office of Research and Development, US EPA, Washington DC, USA

2014- Scientist, Section of IARC Monographs, International Agency for Research on Cancer, Lyon, France

Other Experience and Professional Memberships (selected)

1997- Member, Society of Toxicology
1998- Diplomate, American Board of Toxicology
2002 Board of Scientific Advisors, Bionexus Ventures
2006- Editorial Board Member, *Mutation Research*
2012-2013 Risk Assessment Forum, US Environmental Protection Agency

Honors

2012 Gold Medal for Exceptional Service, US EPA
2010 Scientific and Technological Achievement Award, Level III, US EPA
2008 SOT Award, Best Presentation in Risk Assessment
2008–2011 Outstanding Performance Rating, US EPA
2007–2012 Superior Performance Awards, US EPA
1993 Cornelius W. Krusé Award for outstanding dissertation in Environmental Health Sciences
1991–1992 Meritorious Research Awards from SOT Specialty Sections (Mechanisms, 1991, Carcinogenesis, 1992)
1991 SOT Predoctoral Fellowship, Hoffmann-LaRoche
1991 SOT Student Travel Award
1987–1992 National Research Service Award, Training Grant, sponsored by the National Institute of Environmental Health Sciences

C. Peer-reviewed Publications Relevant to the Proposal (Selected from 58 peer-reviewed publications)

Mechanistic Data Considerations and Evaluations

- Lash LH, Chiu WA, Guyton KZ, Rusyn I. Biotransformation of trichloroethylene: species- and tissue-dependent differences and their importance in human health risk assessment. Mut Res Rev, *in press*.
- Wignall, JA, Shapiro, AJ, Wright, FA, Woodruff, TJ, Chiu, WA, Guyton, KZ, Rusyn, I. Standardizing benchmark dose calculations to improve science-based decisions in human health assessments. 2014 Environ Health Perspect. 122(5): 499-505.
- Guyton, KZ, Hogan, KA, Scott, CS, Cooper, GS, Bale, AS, Kopylev, L, Barone Jr., S, Makris, SL, Glenn, B, Subramaniam, R, Gwinn, MR, Dzubow, RC, Chiu, WA. Human health effects of tetrachloroethylene: Key findings and scientific issues. 2014. Environ Health Perspect.122(4): 325-334.
- Chiu, WA, Campbell Jr., JL, Clewell III, HJ, Zhou, Y-H, Wright, FA, Guyton, KZ, Rusyn, I. Physiologically based pharmacokinetic (PBPK) modeling of interstrain variability in trichloroethylene metabolism in the mouse. 2014. Environ Health Perspect, 122(5): 456-463.
- Rusyn, I, Chiu, WA, Lash, LH, Kromhout, H, Hansen, J, Guyton KZ. Trichloroethylene: mechanistic, epidemiologic, and other supporting evidence of carcinogenic hazard. 2014. Pharmacology and Therapeutics. 141(1): 55-68.
- Kushman ME, Kraft AD, Guyton KZ, Chiu WA, Makris SL, Rusyn I. A systematic approach for identifying and presenting mechanistic evidence in human health assessments. 2013. Reg Tox Pharm, 67(2):266-277.
- Chiu WA, Jinot J, Scott CS, Makris SL, Cooper GS, Dzubow RC, Bale AS, Evans MV, Guyton KZ, Keshava N, Lipscomb JC, Barone S Jr, Fox JF, Gwinn MR, Schaum J, Caldwell JC. Human health effects of trichloroethylene: key findings and scientific issues. 2013. Environ Health Perspect. 121(3):303-11.
- Guha N, Loomis D, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Baan R, Mattock H, Straif K; International Agency for Research on Cancer Monograph Working Group. 2012. Carcinogenicity of trichloroethylene, tetrachloroethylene, some other chlorinated solvents, and their metabolites. Lancet Oncol. Dec;13(12):1192-3.

- Zeise L, Bois FY, Chiu WA, Hattis D, Rusyn I, Guyton KZ. 2012. Addressing human variability in next-generation human health risk assessments of environmental chemicals. Environ Health Perspect. 121(1):23-31.
- Rusyn I, Sedykh A, Low Y, Guyton KZ, Tropsha A. 2012. Predictive modeling of chemical hazard by integrating numerical descriptors of chemical structures and short-term toxicity assay data. Toxicological Sciences, 127(1):1-9.
- Ginsberg G, Angle K, Guyton KZ, Sonawane B. 2011. Polymorphism in the DNA repair enzyme XRCC1: Utility of current database and implications for human health risk assessment. Mutation Research 727(1-2):1-15.
- Gwinn MR, Johns DO, Bateson TF, Guyton KZ. 2011. A review of the genotoxicity of 1,2-dichloroethane (EDC). Mutation Research 727(1-2): 42-53.
- Ginsberg G, Guyton KZ, Johns D, Schimek J, Angle K, Sonawane B. Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment. Crit Rev Toxicol. 2010 40(7):575-619.
- Ginsberg G, Smolenski S, Neafsey P, Hattis D, Walker K, Guyton KZ, Johns DO, Sonawane B. 2009. The influence of genetic polymorphisms on population variability in six xenobiotic-metabolizing enzymes. J Toxicol Environ Health B Crit Rev 12(5-6): 307-333.
- Guyton KZ, Chiu WA, Bateson TF, Jinot J, Scott CS, Brown RC, Caldwell JC. 2009. A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants. Environmental Health Perspectives 117(11): 1664-1672.
- Woodruff TJ, Zeise L, Axelrad DA, Guyton KZ, Janssen S, Miller M, Schwartz JM, Alexeef G, Anderson H, Birnbaum L, Bois F, Cogliano VJ, Crofton K, Euling SY, Foster PM, Germolec DR, Gray E, Hattis DB, Kyle AD, Luebke RW, Luster MI, Portier C, Rice DC, Solomon G, Vandenberg J, Zoeller RT. 2008. Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making. Environmental Health Perspectives 116(11): 1568-1575.
- Guyton KZ, Kyle AD, Aubrecht J, Cogliano VJ, Eastmond DA, Jackson M, Keshava N, Sandy MS, Sonawane B, Zhang L, Waters MD, Smith MT. 2009. Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. Mutation Research 681(2-3): 230-240.
- Guyton KZ, Kensler TW. 1993. Oxidative mechanisms in carcinogenesis. British Medical Bulletin 49(3): 523-544

Primary Research Articles—Mechanisms

- Fawcett TW, Martindale JL, Guyton KZ, Hai T, Holbrook NJ. 1999. Complexes containing activating transcription factor (ATF)/cAMP-responsive-element-binding protein (CREB) interact with the CCAAT/enhancer-binding protein (C/EBP)-ATF composite site to regulate Gadd153 expression during the stress response. The Biochemical Journal 339 (Pt 1): 135-141.
- Guyton KZ, Xu Q, Holbrook NJ. 1996. Induction of the mammalian stress response gene GADD153 by oxidative stress: role of AP-1 element. The Biochemical Journal 314 (Pt 2): 547-554.
- Guyton KZ, Liu Y, Gorospe M, Xu Q, Holbrook NJ. 1996. Activation of mitogen-activated protein kinase by H2O2. Role in cell survival following oxidant injury. The Journal of Biological Chemistry 271(8): 4138-4142.
- Liu Y, Guyton KZ, Gorospe M, Xu Q, Lee JC, Holbrook NJ. 1996. Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. Free Radical Biology & Medicine 21(6): 771-781.

D. Research Support

Principal Investigator (2000–2005); Cancer health effect biomarker contracts supporting the US National Dialog on Cancer, and the US Intra-Agency Oncology Task Force (National Cancer Institute/ Food and Drug Administration) (see *Clinical Cancer Res.*, 2004 10 (11) and 2005 11(8):2785–808). I provided technical input and oversight, building and supervising a multidisciplinary team to achieve timely and successful completion of project goals (receiving outstanding client performance ratings).

International Agency for Research on Cancer

150 cours Albert Thomas
69372 Lyon cedex 08, France

Section of IARC Monographs
Tel.: +33 4 72 73 85 07
Fax: +33 4 72 73 83 19
E-mail: imo@iarc.fr
http://monographs.iarc.fr

Division of Central Grants Processing, OER
National Institutes of Health
6705 Rockledge Drive, MSC 7986,
Suite 5016
Bethesda, MD 20817
USA

Special courier: tel. 1-301-594.6584

Ref.: IMO/43/4

16 June 2014

Grant No 4U01CA033193-32

Dear Sirs,

I enclose our Grant Progress Report for the budget period from 1 September 2013 to 31 August 2014, including the budget request of the next period from 1 September 2014 to 31 August 2015.

The biosketch of one new staff member is included.

I trust the enclosed report is satisfactory and look forward to our continued collaboration.

Yours sincerely,

Kurt Straif, MD, PhD
Head, IARC Monographs Section

ENCL: As mentioned